Clinical Trial Update: A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating talimogene laherparepvec (T-VEC) with or without radiotherapy in melanoma and Merkel cell carcinoma (and other solid tumors) has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Merkel Cell Carcinoma

Drugs mentioned

• T-VEC (talimogene laherparepvec)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma, Merkel Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-29